Latest Breaking News On - Interim data - Page 1 : vimarsana.com

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Palo altoUnited statesAhmed aribiCharlene liaoProduct serviceEuropean hematology associationLeukemia lymphoma society therapy acceleration programDrug administrationNational cancer instituteNational institutes of healthCalifornia institute for regenerative medicineOnc therapeutics incDivision of leukemiaOnc therapeutics announces presentationInterim dataChronic myelomonocytic leukemia

Immunic to Participate in Investor and Scientific Conferences in May

NEW YORK, May 6, 2024 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.

United statesSofiya gradJessica breuEdna kaplanPaula schwartzSonya ivanova hristova chakmakovaRobertj foxFranziska buriExchange commissionMellen centerResearch forumNational congressNeurological instituteRx communications groupConsortium of multiple sclerosis centersImmunic inc

EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in May

EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSofiya gradFranziska buriEdna kaplanJessica breuSonya ivanova hristova chakmakovaPaula schwartzRobertj foxExchange commissionTheconsortium of multiple sclerosis centersDistribution servicesRx communications groupResearch forumNeurological instituteImmunic incMellen center

Molecular Templates Presents Interim Data from MT-6402

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage.

United statesSan diegoEric pomaMolecular templates incExchange commissionAmerican association for cancer research annual meetingInterim dataCancer research annual meetingShiga like toxinLooking statementsPrivate securities litigation reform actMolecular templatesSafe harborMolecular templateNasdaq mtemMolecular templates

Molecular Templates (MTEM) Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at AACR

Molecular Templates (MTEM) Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at AACR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEric pomaMolecular templates incAmerican association for cancer research annual meetingMolecular templatesInterim dataCancer research annual meetingInterim data location